A multi‐purpose Japanese phase I study in the global development of vupanorsen: Randomized, placebo‐controlled, single‐ascending dose study in adults

Vupanorsen (PF‐07285557) is a second‐generation tri‐N‐acetyl galactosamine (GalNAc(3))‐antisense oligonucleotide targeted to angiopoietin‐like 3 (ANGPTL3) mRNA, shown to reduce lipids and apolipoproteins in subjects with dyslipidemia. To aid bringing innovative drugs to global patients efficiently,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuhara, Kei, Furihata, Kenichi, Matsuoka, Nobushige, Itamura, Rio, Ramos, Vesper, Hagi, Toshiaki, Kalluru, Hindu, Bramson, Candace, Terra, Steven G., Liu, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175964/
https://www.ncbi.nlm.nih.gov/pubmed/37002654
http://dx.doi.org/10.1111/cts.13498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175964/
https://www.ncbi.nlm.nih.gov/pubmed/37002654
http://dx.doi.org/10.1111/cts.13498

Ejemplares similares